Brief: Anthera announces the phase 3 solution study with Sollpura
27/12/2016 21:05
Dec 27 (Reuters) - Anthera Pharmaceuticals Inc ANTH.O
* Anthera announces the Phase 3 solution study with Sollpura
in cystic fibrosis patients with exocrine pancreatic
insufficiency demonstrates encouraging results - additional
study needed
Source text for Eikon: ID:nGNXNNRDTa
Further company coverage: ANTH.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Anthera Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Micron, Darden, Kroger, American Outdoor
Brief: Anthera Pharma's Board Approves Personnel Reorganization Plan
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, Netflix, BlueLinx, Micron
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, BlueLinx, Orexigen, Micron
U.S. STOCKS ON THE MOVE-Anthera, Oclaro, Intel, Broadcom, Orexigen, Goldman